Patents by Inventor J. Mark POHL

J. Mark POHL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage form to increase prasterone bioavailability
    Patent number: 9550804
    Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: January 24, 2017
    Assignee: Health Science Funding, LLC
    Inventor: J. Mark Pohl
  • Dosage form to increase prasterone bioavailability
    Patent number: 8900631
    Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: December 2, 2014
    Assignee: Health Science Funding, LLC
    Inventor: J. Mark Pohl
  • Dosage Form to Increase Prasterone Bioavailability
    Publication number: 20140343026
    Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.
    Type: Application
    Filed: August 4, 2014
    Publication date: November 20, 2014
    Applicant: HEALTH SCIENCE FUNDING, LLC
    Inventor: J. Mark POHL
  • Dosage Form to Increase Prasterone Bioavailability
    Publication number: 20120276197
    Abstract: A way to formulate prasterone to both increase its oral bioavailability, and decrease the variability of its oral bioavailability. In contrast to the approach taught by the prior art, the instant approach is amenable to scale-up to commercial scale. Further, the resulting product is amenable to analysis using standard, known quantitative analytical techniques; thus, unlike the prior art approach, the instant approach may be used to manufacture a product in conformity with applicable regulatory standards.
    Type: Application
    Filed: April 23, 2012
    Publication date: November 1, 2012
    Inventor: J. Mark POHL